Reduced FANCD2 Influences Spontaneous SCE and RAD51 Foci
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Structure and Function of the Human Recq DNA Helicases
Zurich Open Repository and Archive University of Zurich Main Library Strickhofstrasse 39 CH-8057 Zurich www.zora.uzh.ch Year: 2005 Structure and function of the human RecQ DNA helicases Garcia, P L Posted at the Zurich Open Repository and Archive, University of Zurich ZORA URL: https://doi.org/10.5167/uzh-34420 Dissertation Published Version Originally published at: Garcia, P L. Structure and function of the human RecQ DNA helicases. 2005, University of Zurich, Faculty of Science. Structure and Function of the Human RecQ DNA Helicases Dissertation zur Erlangung der naturwissenschaftlichen Doktorw¨urde (Dr. sc. nat.) vorgelegt der Mathematisch-naturwissenschaftlichen Fakultat¨ der Universitat¨ Z ¨urich von Patrick L. Garcia aus Unterseen BE Promotionskomitee Prof. Dr. Josef Jiricny (Vorsitz) Prof. Dr. Ulrich H ¨ubscher Dr. Pavel Janscak (Leitung der Dissertation) Z ¨urich, 2005 For my parents ii Summary The RecQ DNA helicases are highly conserved from bacteria to man and are required for the maintenance of genomic stability. All unicellular organisms contain a single RecQ helicase, whereas the number of RecQ homologues in higher organisms can vary. Mu- tations in the genes encoding three of the five human members of the RecQ family give rise to autosomal recessive disorders called Bloom syndrome, Werner syndrome and Rothmund-Thomson syndrome. These diseases manifest commonly with genomic in- stability and a high predisposition to cancer. However, the genetic alterations vary as well as the types of tumours in these syndromes. Furthermore, distinct clinical features are observed, like short stature and immunodeficiency in Bloom syndrome patients or premature ageing in Werner Syndrome patients. Also, the biochemical features of the human RecQ-like DNA helicases are diverse, pointing to different roles in the mainte- nance of genomic stability. -
Genomic Profiling Reveals High Frequency of DNA Repair Genetic
www.nature.com/scientificreports OPEN Genomic profling reveals high frequency of DNA repair genetic aberrations in gallbladder cancer Reham Abdel‑Wahab1,9, Timothy A. Yap2, Russell Madison4, Shubham Pant1,2, Matthew Cooke4, Kai Wang4,5,7, Haitao Zhao8, Tanios Bekaii‑Saab6, Elif Karatas1, Lawrence N. Kwong3, Funda Meric‑Bernstam2, Mitesh Borad6 & Milind Javle1,10* DNA repair gene aberrations (GAs) occur in several cancers, may be prognostic and are actionable. We investigated the frequency of DNA repair GAs in gallbladder cancer (GBC), association with tumor mutational burden (TMB), microsatellite instability (MSI), programmed cell death protein 1 (PD‑1), and its ligand (PD‑L1) expression. Comprehensive genomic profling (CGP) of 760 GBC was performed. We investigated GAs in 19 DNA repair genes including direct DNA repair genes (ATM, ATR , BRCA1, BRCA2, FANCA, FANCD2, MLH1, MSH2, MSH6, PALB2, POLD1, POLE, PRKDC, and RAD50) and caretaker genes (BAP1, CDK12, MLL3, TP53, and BLM) and classifed patients into 3 groups based on TMB level: low (< 5.5 mutations/Mb), intermediate (5.5–19.5 mutations/Mb), and high (≥ 19.5 mutations/Mb). We assessed MSI status and PD‑1 & PD‑L1 expression. 658 (86.6%) had at least 1 actionable GA. Direct DNA repair gene GAs were identifed in 109 patients (14.2%), while 476 (62.6%) had GAs in caretaker genes. Both direct and caretaker DNA repair GAs were signifcantly associated with high TMB (P = 0.0005 and 0.0001, respectively). Tumor PD‑L1 expression was positive in 119 (15.6%), with 17 (2.2%) being moderate or high. DNA repair GAs are relatively frequent in GBC and associated with coexisting actionable mutations and a high TMB. -
Further Insights Into the Regulation of the Fanconi Anemia FANCD2 Protein
University of Rhode Island DigitalCommons@URI Open Access Dissertations 2015 Further Insights Into the Regulation of the Fanconi Anemia FANCD2 Protein Rebecca Anne Boisvert University of Rhode Island, [email protected] Follow this and additional works at: https://digitalcommons.uri.edu/oa_diss Recommended Citation Boisvert, Rebecca Anne, "Further Insights Into the Regulation of the Fanconi Anemia FANCD2 Protein" (2015). Open Access Dissertations. Paper 397. https://digitalcommons.uri.edu/oa_diss/397 This Dissertation is brought to you for free and open access by DigitalCommons@URI. It has been accepted for inclusion in Open Access Dissertations by an authorized administrator of DigitalCommons@URI. For more information, please contact [email protected]. FURTHER INSIGHTS INTO THE REGULATION OF THE FANCONI ANEMIA FANCD2 PROTEIN BY REBECCA ANNE BOISVERT A DISSERTATION SUBMITTED IN PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR THE DEGREE OF DOCTOR OF PHILOSOPHY IN CELL AND MOLECULAR BIOLOGY UNIVERSITY OF RHODE ISLAND 2015 DOCTOR OF PHILOSOPHY DISSERTATION OF REBECCA ANNE BOISVERT APPROVED: Dissertation Committee: Major Professor Niall Howlett Paul Cohen Becky Sartini Nasser H. Zawia DEAN OF THE GRADUATE SCHOOL UNIVERSITY OF RHODE ISLAND 2015 ABSTRACT Fanconi anemia (FA) is a rare autosomal and X-linked recessive disorder, characterized by congenital abnormalities, pediatric bone marrow failure and cancer susceptibility. FA is caused by biallelic mutations in any one of 16 genes. The FA proteins function cooperatively in the FA-BRCA pathway to repair DNA interstrand crosslinks (ICLs). The monoubiquitination of FANCD2 and FANCI is a central step in the activation of the FA-BRCA pathway and is required for targeting these proteins to chromatin. -
Genetic and Genomic Analysis of Hyperlipidemia, Obesity and Diabetes Using (C57BL/6J × TALLYHO/Jngj) F2 Mice
University of Tennessee, Knoxville TRACE: Tennessee Research and Creative Exchange Nutrition Publications and Other Works Nutrition 12-19-2010 Genetic and genomic analysis of hyperlipidemia, obesity and diabetes using (C57BL/6J × TALLYHO/JngJ) F2 mice Taryn P. Stewart Marshall University Hyoung Y. Kim University of Tennessee - Knoxville, [email protected] Arnold M. Saxton University of Tennessee - Knoxville, [email protected] Jung H. Kim Marshall University Follow this and additional works at: https://trace.tennessee.edu/utk_nutrpubs Part of the Animal Sciences Commons, and the Nutrition Commons Recommended Citation BMC Genomics 2010, 11:713 doi:10.1186/1471-2164-11-713 This Article is brought to you for free and open access by the Nutrition at TRACE: Tennessee Research and Creative Exchange. It has been accepted for inclusion in Nutrition Publications and Other Works by an authorized administrator of TRACE: Tennessee Research and Creative Exchange. For more information, please contact [email protected]. Stewart et al. BMC Genomics 2010, 11:713 http://www.biomedcentral.com/1471-2164/11/713 RESEARCH ARTICLE Open Access Genetic and genomic analysis of hyperlipidemia, obesity and diabetes using (C57BL/6J × TALLYHO/JngJ) F2 mice Taryn P Stewart1, Hyoung Yon Kim2, Arnold M Saxton3, Jung Han Kim1* Abstract Background: Type 2 diabetes (T2D) is the most common form of diabetes in humans and is closely associated with dyslipidemia and obesity that magnifies the mortality and morbidity related to T2D. The genetic contribution to human T2D and related metabolic disorders is evident, and mostly follows polygenic inheritance. The TALLYHO/ JngJ (TH) mice are a polygenic model for T2D characterized by obesity, hyperinsulinemia, impaired glucose uptake and tolerance, hyperlipidemia, and hyperglycemia. -
Use of the XRCC2 Promoter for in Vivo Cancer Diagnosis and Therapy
Chen et al. Cell Death and Disease (2018) 9:420 DOI 10.1038/s41419-018-0453-9 Cell Death & Disease ARTICLE Open Access Use of the XRCC2 promoter for in vivo cancer diagnosis and therapy Yu Chen1,ZhenLi1,ZhuXu1, Huanyin Tang1,WenxuanGuo1, Xiaoxiang Sun1,WenjunZhang1, Jian Zhang2, Xiaoping Wan1, Ying Jiang1 and Zhiyong Mao 1 Abstract The homologous recombination (HR) pathway is a promising target for cancer therapy as it is frequently upregulated in tumors. One such strategy is to target tumors with cancer-specific, hyperactive promoters of HR genes including RAD51 and RAD51C. However, the promoter size and the delivery method have limited its potential clinical applications. Here we identified the ~2.1 kb promoter of XRCC2, similar to ~6.5 kb RAD51 promoter, as also hyperactivated in cancer cells. We found that XRCC2 expression is upregulated in nearly all types of cancers, to a degree comparable to RAD51 while much higher than RAD51C. Further study demonstrated that XRCC2 promoter is hyperactivated in cancer cell lines, and diphtheria toxin A (DTA) gene driven by XRCC2 promoter specifically eliminates cancer cells. Moreover, lentiviral vectors containing XRCC2 promoter driving firefly luciferase or DTA were created and applied to subcutaneous HeLa xenograft mice. We demonstrated that the pXRCC2-luciferase lentivirus is an effective tool for in vivo cancer visualization. Most importantly, pXRCC2-DTA lentivirus significantly inhibited the growth of HeLa xenografts in comparison to the control group. In summary, our results strongly indicate that virus-mediated delivery of constructs built upon the XRCC2 promoter holds great potential for tumor diagnosis and therapy. -
FANCJ Regulates the Stability of FANCD2/FANCI Proteins and Protects Them from Proteasome and Caspase-3 Dependent Degradation
FANCJ regulates the stability of FANCD2/FANCI proteins and protects them from proteasome and caspase-3 dependent degradation Komaraiah Palle, Ph.D. (Kumar) Assistant Professor of Oncologic Sciences Abraham Mitchell Cancer Research Scholar Mitchell Cancer Institute University of South Alabama Outline • Fanconi anemia (FA) pathway • Role of FA pathway in Genome maintenance • FANCJ and FANCD2 functional relationship • FANCJ-mediated DDR in response to Fork-stalling Fanconi Anemia • Rare, inherited blood disorder. • 1:130,000 births Guido Fanconi 1892-1979 • Affects men and women equally. • Affects all racial and ethnic groups – higher incidence in Ashkenazi Jews and Afrikaners Birth Defects Fanconi anemia pathway • FA is a rare chromosome instability syndrome • Autosomal recessive disorder (or X-linked) • Developmental abnormalities • 17 complementation groups identified to date • FA pathway is involved in DNA repair • Increased cancer susceptibility - many patients develop AML - in adults solid tumors Fanconi Anemia is an aplastic anemia FA patients are prone to multiple types of solid tumors • Increased incidence and earlier onset cancers: oral cavity, GI and genital and reproductive tract head and neck breast esophagus skin liver brain Why? FA is a DNA repair disorder • FA caused by mutations in 17 genes: FANCA FANCF FANCM FANCB FANCG/XRCC9 FANCN/PALB2 FANCC FANCI RAD51C/FANCO FANCD1/BRCA2 FANCJ SLX4/FANCP FANCD2 FANCL ERCC2/XPF/FANCQ FANCE BRCA1/FANCS • FA genes function in DNA repair processes • FA patient cells are highly sensitive -
Complex Interacts with WRN and Is Crucial to Regulate Its Response to Replication Fork Stalling
Oncogene (2012) 31, 2809–2823 & 2012 Macmillan Publishers Limited All rights reserved 0950-9232/12 www.nature.com/onc ORIGINAL ARTICLE The RAD9–RAD1–HUS1 (9.1.1) complex interacts with WRN and is crucial to regulate its response to replication fork stalling P Pichierri, S Nicolai, L Cignolo1, M Bignami and A Franchitto Department of Environment and Primary Prevention, Istituto Superiore di Sanita`, Rome, Italy The WRN protein belongs to the RecQ family of DNA preference toward substrates that mimic structures helicases and is implicated in replication fork restart, but associated with stalled replication forks (Brosh et al., how its function is regulated remains unknown. We show 2002; Machwe et al., 2006) and WS cells exhibit that WRN interacts with the 9.1.1 complex, one of enhanced instability at common fragile sites, chromo- the central factors of the replication checkpoint. This somal regions especially prone to replication fork interaction is mediated by the binding of the RAD1 stalling (Pirzio et al., 2008). How WRN favors recovery subunit to the N-terminal region of WRN and is of stalled forks and prevents DNA breakage upon instrumental for WRN relocalization in nuclear foci and replication perturbation is not fully understood. It has its phosphorylation in response to replication arrest. We been suggested that WRN might facilitate replication also find that ATR-dependent WRN phosphorylation restart by either promoting recombination or processing depends on TopBP1, which is recruited by the 9.1.1 intermediates at stalled forks in a way that counteracts complex in response to replication arrest. Finally, we unscheduled recombination (Franchitto and Pichierri, provide evidence for a cooperation between WRN and 2004; Pichierri, 2007; Sidorova, 2008). -
Rad51c Deficiency Destabilizes XRCC3, Impairs Recombination and Radiosensitizes S/G2-Phase Cells
Lawrence Berkeley National Laboratory Lawrence Berkeley National Laboratory Title Rad51C deficiency destabilizes XRCC3, impairs recombination and radiosensitizes S/G2- phase cells Permalink https://escholarship.org/uc/item/2fp0538b Authors Lio, Yi-Ching Schild, David Brenneman, Mark A. et al. Publication Date 2004-05-01 Peer reviewed eScholarship.org Powered by the California Digital Library University of California Rad51C deficiency destabilizes XRCC3, impairs recombination and radiosensitizes S/G2-phase cells Yi-Ching Lio1, 2,*, David Schild1, Mark A. Brenneman3, J. Leslie Redpath2 and David J. Chen1 1Life Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, CA 94720, USA; 2Department of Radiation Oncology, University of California, Irvine, Irvine, CA 92697, USA; 3Department of Genetics, Rutgers University, Piscataway, NJ 08854, USA. * To whom correspondence should be addressed: Yi-Ching Lio MS74-157, Life Sciences Division Lawrence Berkeley National Laboratory One Cyclotron Road Berkeley, CA 94720 Phone: (510) 486-5861 Fax: (510) 486-6816 e-mail: [email protected] Running title: Human Rad51C functions in homologous recombination Total character count: 52621 1 ABSTRACT The highly conserved Rad51 protein plays an essential role in repairing DNA damage through homologous recombination. In vertebrates, five Rad51 paralogs (Rad51B, Rad51C, Rad51D, XRCC2, XRCC3) are expressed in mitotically growing cells, and are thought to play mediating roles in homologous recombination, though their precise functions remain unclear. Here we report the use of RNA interference to deplete expression of Rad51C protein in human HT1080 and HeLa cells. In HT1080 cells, depletion of Rad51C by small interfering RNA caused a significant reduction of frequency in homologous recombination. The level of XRCC3 protein was also sharply reduced in Rad51C-depleted HeLa cells, suggesting that XRCC3 is dependent for its stability upon heterodimerization with Rad51C. -
PALB2 Genetic Testing for Breast Cancer Risk
Lab Management Guidelines V2.0.2021 PALB2 Genetic Testing for Breast Cancer Risk MOL.TS.251.A v2.0.2021 Procedure addressed The inclusion of any procedure code in this table does not imply that the code is under management or requires prior authorization. Refer to the specific Health Plan's procedure code list for management requirements. Procedure(s) addressed by this Procedure code(s) guideline PALB2 Known Familial Mutation Analysis 81308 PALB2 Sequencing 81307 PALB2 Deletion/Duplication Analysis 81479 What is PALB2 genetic testing Definition Breast cancer is the most frequently diagnosed malignancy and the leading cause of cancer mortality in women around the world. Hereditary breast cancer accounts for 5% to 10% of all breast cancer cases. Screening with breast magnetic resonance imaging (MRI) is recommended for women with a greater than 20% lifetime risk for disease based on estimates of risk models that are largely dependent on family history. A large body of evidence indicates that an increased lifetime risk of >20% can also be established through genetic testing. In particular, two cancer susceptibility genes, BRCA1 and BRCA2, are implicated in about 20% of all hereditary breast cancer cases. Other genes have also been identified in the literature as being associated with inherited breast cancer risk, including ATM, CDH1, CHEK2, NBN, NF1, PALB2, PTEN, STK11, and TP53.1,2 In particular, PALB2 is a gene that encodes a protein that may be involved in tumor suppression, and is considered a partner and localizer of BRCA2. Specifically, ~50 truncating mutations in PALB2 have been detected among breast cancer families worldwide. -
Distinct Roles of BRCA2 in Replication Fork Protection in Response to Hydroxyurea and DNA Interstrand Cross-Links
Downloaded from genesdev.cshlp.org on October 1, 2021 - Published by Cold Spring Harbor Laboratory Press Distinct roles of BRCA2 in replication fork protection in response to hydroxyurea and DNA interstrand cross-links Kimberly A. Rickman,1 Raymond J. Noonan,1 Francis P. Lach,1 Sunandini Sridhar,1 Anderson T. Wang,1,5 Avinash Abhyankar,2 Athena Huang,1 Michael Kelly,3 Arleen D. Auerbach,4 and Agata Smogorzewska1 1Laboratory of Genome Maintenance, The Rockefeller University, New York, New York 10065, USA; 2New York Genome Center, New York, New York 10013, USA; 3Tufts Medical Center, Boston, Massachusetts 02111, USA; 4Human Genetics and Hematology, The Rockefeller University, New York, New York 10065, USA DNA interstrand cross-links (ICLs) are a form of DNA damage that requires the interplay of a number of repair proteins including those of the Fanconi anemia (FA) and the homologous recombination (HR) pathways. Pathogenic variants in the essential gene BRCA2/FANCD1, when monoallelic, predispose to breast and ovarian cancer, and when biallelic, result in a severe subtype of Fanconi anemia. BRCA2 function in the FA pathway is attributed to its role as a mediator of the RAD51 recombinase in HR repair of programmed DNA double-strand breaks (DSB). BRCA2 and RAD51 functions are also required to protect stalled replication forks from nucleolytic degradation during re- sponse to hydroxyurea (HU). While RAD51 has been shown to be necessary in the early steps of ICL repair to prevent aberrant nuclease resection, the role of BRCA2 in this process has not been described. Here, based on the analysis of BRCA2 DNA-binding domain (DBD) mutants (c.8488-1G>A and c.8524C>T) discovered in FA patients presenting with atypical FA-like phenotypes, we establish that BRCA2 is necessary for the protection of DNA at ICLs. -
Overexpression of Rad51c Splice Variants in Colorectal Tumors
www.impactjournals.com/oncotarget/ Oncotarget, Vol. 6, No. 11 Overexpression of Rad51C splice variants in colorectal tumors Arjun Kalvala1, Li Gao1, Brittany Aguila1, Tyler Reese1, Gregory A. Otterson1,2, Miguel A. Villalona-Calero1,2,3 and Wenrui Duan1,2 1 Comprehensive Cancer Center, The Ohio State University College of Medicine and Public Health, Columbus, Ohio, U.S.A 2 Division of Medical Oncology Department of Internal Medicine, The Ohio State University College of Medicine and Public Health, Columbus, Ohio, U.S.A 3 Department of Pharmacology at The Ohio State University College of Medicine and Public Health, Columbus, Ohio, U.S.A Correspondence to: Miguel A. Villalona-Calero, email: [email protected] Correspondence to: Wenrui Duan, email: [email protected] Keywords: Rad51C isoform overexpression, Promoter methylation, Colorectal tumors Received: July 29, 2014 Accepted: December 24, 2014 Published: December 30, 2014 This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. ABSTRACT Functional alterations in Rad51C are the cause of the Fanconi anemia complementation group O (FANCO) gene disorder. We have identified novel splice variants of Rad51C mRNA in colorectal tumors and cells. The alternatively spliced transcript variants are formed either without exon-7 (variant 1), without exon 6 and 7 (variant 2) or without exon 7 and 8 (variant 3). Real time PCR analysis of nine pair-matched colorectal tumors and non-tumors showed that variant 1 was overexpressed in tumors compared to matched non- tumors. -
Fanconi Anemia D2 Protein Confers Chemoresistance in Response to the Anticancer Agent, Irofulven
3153 Fanconi anemia D2 protein confers chemoresistance in response to the anticancer agent, irofulven Yutian Wang,1 Timothy Wiltshire,2 Jamie Senft,1 Introduction 3 1,2 Sharon L. Wenger, Eddie Reed, Fanconi anemia is a genetic cancer-susceptibility syn- and Weixin Wang1,2 drome characterized by congenital abnormalities, bone marrow failure, and cellular sensitivity to DNA cross- 1 2 Mary Babb Randolph Cancer Center, Department of linking agents (1, 2). There are at least 12 Fanconi anemia Microbiology, Immunology, and Cell Biology, and 3Department of Pathology, West Virginia University School of Medicine, complementation groups (A, B, C, D1, D2, E, F, G, I, J, L, Morgantown, West Virginia and M), and 10 Fanconi anemia genes (A, C, D1/BRCA2, D2, E, F, G, J, L, and M) have been cloned (1–8). All of the Fanconi anemia proteins function in a common path- Abstract way. Fanconi anemia proteins (A, B, C, E, F, G, L, and M) The Fanconi anemia-BRCA pathway of genes are fre- assemble in a nuclear complex that is required for mono- quently mutated or epigenetically repressed in human ubiquitination/activation of the downstream FANCD2 cancer. The proteins of this pathway play pivotal roles in protein (1, 2, 4, 6, 9–13). FANCL has been shown to DNA damage signaling and repair. Irofulven is one of a possess the E3 ubiquitin ligase activity to monoubiqui- new class of anticancer agents that are analogues of tinate FANCD2at Lys 561 (11). The deubiquitinating mushroom-derived illudin toxins. Preclinical studies and enzyme of FANCD2, USP1, has also been recently clinical trials have shown that irofulven is effective identified (14).